Cargando…

Colorectal cancer and NF-κB signaling pathway

Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been made in the development of chemotherapy for advanced CRC. Targeted therapies against VEGF or EGFR are now commonly used. However, many cases show that tolerance develops to such treatments; therefore, new strategi...

Descripción completa

Detalles Bibliográficos
Autor principal: Hassanzadeh, Parichehr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Institute for Gastroenterology and Liver Diseases 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017424/
https://www.ncbi.nlm.nih.gov/pubmed/24834170
_version_ 1782479948699664384
author Hassanzadeh, Parichehr
author_facet Hassanzadeh, Parichehr
author_sort Hassanzadeh, Parichehr
collection PubMed
description Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been made in the development of chemotherapy for advanced CRC. Targeted therapies against VEGF or EGFR are now commonly used. However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies. Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemo- and radio- therapies. Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target.
format Online
Article
Text
id pubmed-4017424
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Research Institute for Gastroenterology and Liver Diseases
record_format MEDLINE/PubMed
spelling pubmed-40174242014-05-15 Colorectal cancer and NF-κB signaling pathway Hassanzadeh, Parichehr Gastroenterol Hepatol Bed Bench Research Article Colorectal cancer (CRC) is the second leading cause of cancer death. Progress has been made in the development of chemotherapy for advanced CRC. Targeted therapies against VEGF or EGFR are now commonly used. However, many cases show that tolerance develops to such treatments; therefore, new strategies are required to replace or complement current therapies. Nuclear factor-κB (NF-κB) transcription factors play a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signaling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemo- and radio- therapies. Hence, anti-NF-κB therapy may rescue many cases of CRC and should be considered as a therapeutic target. Research Institute for Gastroenterology and Liver Diseases 2011 /pmc/articles/PMC4017424/ /pubmed/24834170 Text en Copyright © 2011 Research Institute for Gastroenterology and Liver Diseases http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Research Article
Hassanzadeh, Parichehr
Colorectal cancer and NF-κB signaling pathway
title Colorectal cancer and NF-κB signaling pathway
title_full Colorectal cancer and NF-κB signaling pathway
title_fullStr Colorectal cancer and NF-κB signaling pathway
title_full_unstemmed Colorectal cancer and NF-κB signaling pathway
title_short Colorectal cancer and NF-κB signaling pathway
title_sort colorectal cancer and nf-κb signaling pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017424/
https://www.ncbi.nlm.nih.gov/pubmed/24834170
work_keys_str_mv AT hassanzadehparichehr colorectalcancerandnfkbsignalingpathway